Document Detail

Stat3 - Linking inflammation to (gastrointestinal) tumourigenesis.
MedLine Citation:
PMID:  22211709     Owner:  NLM     Status:  Publisher    
Tumourigenesis is a multistage process comprising initiation, promotion and progression that is governed by cumulative (epi-)genetic changes. However, tumour initiation, triggered by mutations in proto-oncogenes and/or tumour suppressor genes, is insufficient for the development of cancers. Tumour promotion often depends on the interaction between initiated cells and the microenvironment where excessive abundance of inflammatory mediators, including those of the interleukin (IL-)6/gp130 family, promote their expansion. The activity of most soluble mediators ultimately converge on tumour cells through activation of the latent transcription factors NF-κB and Stat3 to enhance survival of neoplastic cells. In addition, Stat3 also promotes tumour cell proliferation, invasion and induction of an angiogenic switch. Persistent activation of STAT3 is a unifying hallmark of a majority of solid malignancies. However, persistent STAT3 activation occurs usually in the absence of activating mutations in, or amplification of, the STAT3 gene. Instead, it is associated with an oversupply of autocrine and/or paracrine activating cytokines secreted by tumour and stromal cells and comprising (among others) cytokines that utilize the gp130 receptor. IL6, IL11 and other members of the gp130 cytokine family have been identified in preclinical mouse models as promising therapeutic targets for gastrointestinal, hepatic and breast cancers. Thus, pharmacological interference with specific cytokines and tyrosine kinases that trigger Stat3 activation affords opportunities to therapeutically target the non-redundant tumour promoting signalling function of Stat3. © 2011 The Authors Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.
Matthias Ernst; Tracy L Putoczki
Related Documents :
22227579 - Evidence for activation of mutated p53 by apigenin in human pancreatic cancer.
21625639 - Sphingosine kinase 1 regulates the akt/foxo3a/bim pathway and contributes to apoptosis ...
7721259 - Pituitary-thyroid axis and immune system: a reciprocal neuroendocrine-immune interaction.
3907369 - Sex hormones, immune responses, and autoimmune diseases. mechanisms of sex hormone action.
14703019 - Effects of growth hormone and prolactin on adipose tissue development and function.
18802199 - Androgens play a pivotal role in maintaining penile tissue architecture and erection: a...
20300429 - Cytokines and their stats in cutaneous and visceral leishmaniasis.
20181529 - B-cells need a proper house, whereas t-cells are happy in a cave: the dependence of lym...
25266899 - Probiotic bacillus pumilus se5 shapes the intestinal microbiota and mucosal immunity in...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-12-28
Journal Detail:
Title:  Clinical and experimental pharmacology & physiology     Volume:  -     ISSN:  1440-1681     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2012-1-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0425076     Medline TA:  Clin Exp Pharmacol Physiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 The Authors Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.
Ludwig Institute for Cancer Research, Melbourne Parkville Branch, AUSTRALIA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Home care in Austria: the interplay of family orientation, cash-for-care and migrant care.
Next Document:  Comparison of Outcomes and the Use of Multimodality Therapy in Young and Elderly People Undergoing S...